GregoryQMarsellaMD

Summary

• Greg Marsella is a co-founder of Da Vinci Research Institute, a small, independent clinical research company that does grant-based medical research and also offers local, contract research services to Fortune 500 pharmaceutical companies, biotechnology companies, and national CRO’s. Dr. Marsella is a physician by training and a board-certified psychiatrist who received his B.A. at Harvard, his M.D. at the University of Pennsylvania, and his residency training in psychiatry at New York Hospital-Cornell Medical Center. In addition to its other missions Da Vinci Research Institute is a medical research network furnishing study-procural, patient-recruitment, site-management, and research administrative services for its participating practices in Florida. Dr. Marsella has been a site investigator for Phase II, III, and IV multicenter, nationwide clinical trials, and has also authored and implemented grant-based medical research studies in child and adult psychopharmacology, neurology, epilepsy medicine, and pain-management.
  
  SHORT SAMPLE OF PHASE II-IV MULTICENTER TRIALS, AND INVESTIGATOR-AUTHORED, GRANT-SUBSIDIZED RESEARCH, IN WHICH DR. MARSELLA WAS A PRINCIPAL INVESTIGATOR
  
  1. “A Placebo-Controlled Study of Olanzapine in the Treatment of Bipolar I Depression.” (Eli Lilly)
  2. “An Open-Label Evaluation of Lamotrigine Versus Carbamapezine, Phenytoin, and Divalproex Sodium as Monotherapy for Epilepsy Patients Who Have Failed a Previous Course of AED Therapy.” (GlaxoSmithKline)
  3. “A 6-Month, Multi-Center, Placebo-Controlled, Chronic Migraine Treatment Trial with Topamax and either Propranolol or Placebo.” (NIH/National Institute of Neurological Disorders and Stroke)
  4. “Risperidone in the Treatment of Children with Autism Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety.” (Johnson & Johnson)
  5. “A 6-Week, Double-Blind, Placebo-Controlled, Multicenter Trial of Varenicline for Cognitive Impairment in Subjects with Schizophrenia.” (Pfizer)